VivoSeq
Hematology

Acquired Hemophilia

9

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Acquired Hemophilia is an early-stage landscape with 9 programs across 3 companies. The most active players are Roche, Pfizer, Takeda. 1 therapy is approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

80/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 2Pfizer logo

Pfizer

1 program

Phase 3Takeda logo

Takeda

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody240%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

11

clinical trials

Completed4 · 36%
Recruiting3 · 27%
Active, not recruiting1 · 9%
No longer available1 · 9%
Terminated1 · 9%
Unknown status1 · 9%

Clinical Trials

Trial Activity

11 trials

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT05849740·25 enrolled
A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
Recruiting·Takeda logoTakeda·N/A·NCT06550882·9 enrolled
General Use-results Survey of OBIZUR for I.V. Injection (All-case Surveillance)
Recruiting·Takeda logoTakeda·N/A·NCT06461533·25 enrolled
Emicizumab in Patients With Acquired Hemophilia A
Active, not recruiting·UUniversity of Washington·Phase 2·NCT05345197·51 enrolled
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Completed·BBaxalta now part of Shire·N/A·NCT02610127·53 enrolled
Emicizumab in Acquired Hemophilia A
Completed·GGWT-TUD GmbH·Phase 2·NCT04188639·47 enrolled
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Completed·BBaxalta now part of Shire·Phase 2/3·NCT01178294·29 enrolled
Study of TAK-672 in Participants With Acquired Hemophilia A
Completed·Takeda logoTakeda·Phase 2/3·NCT04580407·5 enrolled
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
Terminated·GGeorgetown University·Phase 2/3·NCT00306670·2 enrolled
Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
No longer available·BBaxalta now part of Shire·N/A·NCT01968655
Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT03700229·22 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)